AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21142844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside and protease inhibitor antiretroviral therapy (ARV) after first trimester
Number of subjects: 1414
Study 21142844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside and protease inhibitor antiretroviral therapy (ARV)
Number of subjects: 1414
Study 18955451 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 428
Study 18955451 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 428
Study 18955451 — intervention group
Group type: COMPARATOR
Intervention: KIT exon 9-mutant genotype
Number of subjects: 428
Study 18955451 — intervention group
Group type: COMPARATOR
Intervention: Wild-type (WT) genotype
Number of subjects: 428
Study 18955451 — intervention group
Group type: EXPERIMENTAL
Intervention: CD117-negative GIST
Number of subjects: 428
Study 16606651 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 254
Study 16606651 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept and sulfasalazine
Number of subjects: 254
Study 16606651 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 254
Study 16606651 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept alone
Number of subjects: 254
Study 15062131 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I episcleral plaque radiotherapy (EPRT) with median dose of 80.0 Gy
Number of subjects: 35
Study 15062131 — intervention group
Group type: EXPERIMENTAL
Intervention: Episcleral hyperthermia (HT) with median temperature of 44 degrees C
Number of subjects: 35
Study 15062131 — intervention group
Group type: COMPARATOR
Intervention: 125I episcleral plaque radiotherapy (EPRT) with median dose of 60.8 Gy
Number of subjects: 35
Study 10824374 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing assessment
Number of subjects: 23
Study 10824374 — intervention group
Group type: COMPARATOR
Intervention: Face to face (FTF) assessment
Number of subjects: 23
Study 10824374 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry system
Number of subjects: 23
Study 10824374 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing system
Number of subjects: 23
Study 8856682 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presence of the first tone (sustained neural activity)
Number of subjects: 0
Study 8856682 — intervention group
Group type: COMPARATOR
Intervention: Preceding tone (control condition)
Number of subjects: 0
Study 8856682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (sustained vs persisting neural activity)
Number of subjects: 0
Study 6371152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms per dose)
Number of subjects: 149
Study 6371152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 30724660 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 1378
Study 28835254 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinely recorded clinical and non-clinical data access
Number of subjects: 98
Study 25912588 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (80 mg/d) and atorvastatin (20 mg/d)
Number of subjects: 200
Study 25912588 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril (10 mg/d) and atorvastatin (20 mg/d)
Number of subjects: 200
Study 24590419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance intervention (MS Body Project)
Number of subjects: 133
Study 24590419 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 133
Study 23015654 — intervention group
Group type: COMPARATOR
Intervention: IGF‐I serum levels in men (137 ± 69 ng/ml for AD)
Number of subjects: 694
Study 23015654 — intervention group
Group type: COMPARATOR
Intervention: IGFBP‐3 serum levels in men (3675 ± 1542 ng/ml for AD)
Number of subjects: 694
Study 23015654 — intervention group
Group type: COMPARATOR
Intervention: IGFBP‐3 serum levels in women (3781 ± 1351 ng/ml for AD)
Number of subjects: 694
Study 23015654 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I odds ratio in men
Number of subjects: 694
Study 23015654 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP‐3 odds ratio in men
Number of subjects: 694
Study 19562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Reniale (autologous tumour cell lysate vaccination therapy)
Number of subjects: 990
Study 19562320 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant treatment)
Number of subjects: 990
Study 19562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Reniale (for patients with pT3 RCC)
Number of subjects: 990
Study 19562320 — intervention group
Group type: COMPARATOR
Intervention: Control (for patients with pT3 RCC)
Number of subjects: 990
Study 19562320 — intervention group
Group type: COMPARATOR
Intervention: Control (median survival for patients with pT3 RCC)
Number of subjects: 990
Study 19562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Reniale (Cox analysis)
Number of subjects: 990
Study 19562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Reniale (Cox analysis for pT3 tumours)
Number of subjects: 990
Study 17898346 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 161
Study 17898346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 15824468 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE+ Japan follow-up group (n=18)
Number of subjects: 57
Study 15824468 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 57
Study 11523669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hypertensive hemodilution fluid therapy
Number of subjects: 32
Study 11523669 — intervention group
Group type: COMPARATOR
Intervention: Normovolemic fluid therapy
Number of subjects: 32
Study 9629947 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI
Number of subjects: 42
Study 9629947 — intervention group
Group type: EXPERIMENTAL
Intervention: BPII
Number of subjects: 42
Study 7938758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 151
Study 7938758 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 151
Study 3284630 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/day) for six weeks
Number of subjects: 47
Study 3284630 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six weeks
Number of subjects: 47
Study 31313886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal glasses
Number of subjects: 119
Study 31313886 — intervention group
Group type: COMPARATOR
Intervention: Unifocal glasses
Number of subjects: 119
Study 29174273 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed, encapsulated placenta (n=12)
Number of subjects: 27
Study 29174273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 27
Study 29489108 — intervention group
Group type: EXPERIMENTAL
Intervention: Support ventilation modes during anesthesia
Number of subjects: 0
Study 24258498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 34
Study 24028542 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening doors and windows with metal mesh and closing openings on eves and walls by mud
Number of subjects: 40
Study 24028542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 20428621 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS) with expiratory positive airway pressure (EPAP)
Number of subjects: 16
Study 20428621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 17692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension formulation of acyclovir 400 mg
Number of subjects: 50
Study 17692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of acyclovir 400 mg
Number of subjects: 50
Study 14757326 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH(1)-receptor-antagonist R121919 (higher doses)
Number of subjects: 27
Study 14757326 — intervention group
Group type: COMPARATOR
Intervention: CRH(1)-receptor-antagonist R121919 (lower doses)
Number of subjects: 27
Study 14757326 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH(1)-receptor-antagonist R121919
Number of subjects: 27
Study 11288847 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic bolus tracking (n = 20)
Number of subjects: 40
Study 11288847 — intervention group
Group type: COMPARATOR
Intervention: Time delay (n = 20)
Number of subjects: 40
Study 9709744 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (standard intensity)
Number of subjects: 18
Study 9709744 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (less than standard intensity)
Number of subjects: 18
Study 7995861 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat feeding
Number of subjects: 32
Study 7995861 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric feeding
Number of subjects: 32
Study 3135010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 100
Study 3135010 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (in non-smoking men)
Number of subjects: 100
Study 3135010 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (in smokers)
Number of subjects: 100
Study 3135010 — intervention group
Group type: COMPARATOR
Intervention: General treatment for women
Number of subjects: 100
Study 29407665 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention in driving schools
Number of subjects: 1866
Study 29407665 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR genotype (S'-allele carriers)
Number of subjects: 1866
Study 29407665 — intervention group
Group type: EXPERIMENTAL
Intervention: L'/L' homozygotes
Number of subjects: 1866
Study 26754071 — intervention group
Group type: EXPERIMENTAL
Intervention: FENIX magnetic sphincter augmentation (MSA)
Number of subjects: 350
Study 26754071 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 350
Study 25635887 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator
Number of subjects: 250
Study 25635887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 23725681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 38
Study 23725681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19878097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline/hydroxyethyl starch (HSH)
Number of subjects: 49
Study 19878097 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution (CT group)
Number of subjects: 49
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of a living will
Number of subjects: 356
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of cardiopulmonary resuscitation performed in the last hour of life
Number of subjects: 356
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of tube feeding
Number of subjects: 356
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence at time of death
Number of subjects: 356
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of the patient's wish to withdraw life support during a family conference
Number of subjects: 356
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of standardized comfort care orders
Number of subjects: 356
Study 18379239 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of a family conference
Number of subjects: 356
Study 16677742 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel's milk
Number of subjects: 8
Study 16677742 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 8
Study 15130632 — intervention group
Group type: EXPERIMENTAL
Intervention: CeeOn Edge 911A
Number of subjects: 288
Study 15130632 — intervention group
Group type: COMPARATOR
Intervention: AcrySof MA60BM
Number of subjects: 288
Study 15130632 — intervention group
Group type: COMPARATOR
Intervention: PhacoFlex SI-40NB
Number of subjects: 288
Study 11486922 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvilinear source-identification ROCs across various encoding and test conditions
Number of subjects: 0
Study 11486922 — intervention group
Group type: EXPERIMENTAL
Intervention: Source-monitoring framework
Number of subjects: 0
Study 9609409 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen intravenously (i.v.)
Number of subjects: 26
Study 9609409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7924774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-birth-weight infants (<2.5 kg)
Number of subjects: 232
Study 7924774 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants small for gestational age
Number of subjects: 232
Study 7924774 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with corrected birth weight: length ratio below the 10th percentile
Number of subjects: 232
Study 7924774 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with corrected 6-month weight below the 10th percentile
Number of subjects: 232
Study 7924774 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed infants for 6 months
Number of subjects: 232
Study 3071597 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995
Number of subjects: 2
Study 3071597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30676200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (infusion resulting in an arterial blood alcohol concentration of 80 mg%)
Number of subjects: 54
Study 30676200 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (saline infusion)
Number of subjects: 54
Study 30676200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 54
Study 28650788 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac system
Number of subjects: 60
Study 28650788 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional needle irrigation
Number of subjects: 60
Study 28650788 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl) + ethylenediaminetetraacetic acid (EDTA)
Number of subjects: 60
Study 28650788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated water (OW) + EDTA
Number of subjects: 60
Study 28650788 — intervention group
Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 60
Study 28650788 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 25873213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (standard dose, monthly review)
Number of subjects: 1000
Study 25873213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (low dose, monthly review)
Number of subjects: 1000
Study 25873213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (standard dose, two-monthly review)
Number of subjects: 1000
Study 25873213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (low dose, two-monthly review)
Number of subjects: 1000
Study 23001556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg, increased to 70 mg over 4 weeks and maintained for another 4 weeks
Number of subjects: 63
Study 23001556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 23001556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 63
Study 23001556 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) and Placebo
Number of subjects: 63
Study 21425570 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medical therapy (Chinese drugs)
Number of subjects: 36
Study 21425570 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic therapy only)
Number of subjects: 36
Study 19178385 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (thrice weekly 45‐min intervals)
Number of subjects: 30
Study 19178385 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (three 45‐min episodes of stretching, balance training and coordination)
Number of subjects: 30
Study 16172624 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g of creatine monohydrate daily for 6 days)
Number of subjects: 6
Study 16172624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, daily for 6 days)
Number of subjects: 6
Study 16172624 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 6
Study 16172624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 14520721 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β2-adrenoceptor agonists (LABAs)
Number of subjects: 8
Study 14520721 — intervention group
Group type: COMPARATOR
Intervention: Long-acting β2-adrenoceptor agonists (LABAs) with regular maintenance with inhaled corticosteroids (ICS)
Number of subjects: 8
Study 10944595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy (given to 77 patients, 65%)
Number of subjects: 119
Study 10944595 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 119
Study 10944595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy
Number of subjects: 119
Study 9291399 — intervention group
Group type: EXPERIMENTAL
Intervention: alfusozine
Number of subjects: 249
Study 9291399 — intervention group
Group type: EXPERIMENTAL
Intervention: carbachol/diazepam
Number of subjects: 249
Study 9291399 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 249
Study 8349935 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg intranasal)
Number of subjects: 14
Study 8349935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3091373 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin Brand 1
Number of subjects: 38
Study 3091373 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin Brand 2
Number of subjects: 38
Study 3091373 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl-penicillin potassium
Number of subjects: 38
Study 28822559 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (7 days of oral metronidazole and ciprofloxacin)
Number of subjects: 307
Study 28822559 — intervention group
Group type: COMPARATOR
Intervention: Standard care without antibiotics
Number of subjects: 307
Study 27062352 — intervention group
Group type: COMPARATOR
Intervention: Closed suction drain placement
Number of subjects: 0
Study 24714011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 μg plus 3 ml of 0.5% hyperbaric bupivacaine (Group FB)
Number of subjects: 186
Study 24714011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group TB)
Number of subjects: 186
Study 24714011 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus 3 ml of 0.5% hyperbaric bupivacaine (Group SB)
Number of subjects: 186
Study 22992271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency tonsillectomy
Number of subjects: 300
Study 22992271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery tonsillectomy
Number of subjects: 300
Study 22992271 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scalpel tonsillectomy
Number of subjects: 300
Study 22992271 — intervention group
Group type: COMPARATOR
Intervention: Cold steel dissection tonsillectomy
Number of subjects: 300
Study 19740393 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg alone
Number of subjects: 12
Study 19740393 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg with omeprazole 40 mg (administered 15 min before imatinib on day 5)
Number of subjects: 12
Study 19740393 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg with omeprazole 40 mg
Number of subjects: 12
Study 17711168 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematized care plan
Number of subjects: 256
Study 17711168 — intervention group
Group type: COMPARATOR
Intervention: Conventional care plan
Number of subjects: 256
Study 14692022 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of Zoledronic acid (Zol)
Number of subjects: 1130
Study 14692022 — intervention group
Group type: COMPARATOR
Intervention: 90 mg of Pamidronate (Pam)
Number of subjects: 1130
Study 11207631 — intervention group
Group type: COMPARATOR
Intervention: Testosterone alone (group 1, n = 10)
Number of subjects: 23
Study 11207631 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone with 10 mg oestradiol (group 2, n = 7)
Number of subjects: 23
Study 11207631 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone with 20 mg oestradiol (group 3, n = 6)
Number of subjects: 23
Study 9734787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health advisers recommended screening and offered a convenient screening opportunity
Number of subjects: 100
Study 8037337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-intensive regimen
Number of subjects: 0
Study 8037337 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study 2720925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus gamma-globulin, 400 mg/kg/day for 4 consecutive days (n = 28, 60%)
Number of subjects: 98
Study 2720925 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n = 19, 40%)
Number of subjects: 98
Study 2720925 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 98
Study 28945641 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week finger grip training program (suspensions on small holds, 2 times a week)
Number of subjects: 14
Study 28945641 — intervention group
Group type: COMPARATOR
Intervention: Climbing exercises only (control group)
Number of subjects: 14
Study 28034891 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-FVIII NNAs
Number of subjects: 237
Study 28034891 — intervention group
Group type: COMPARATOR
Intervention: Absence of anti-FVIII NNAs
Number of subjects: 237
Study 25500348 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Tics (LWT) intervention
Number of subjects: 24
Study 25500348 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24